Results 161 to 170 of about 6,297,770 (215)

El dolor en la esclerosis múltiple

Acta Neurológica Colombiana, 2023
Jorge Luis Sánchez Múnera.
doaj   +2 more sources

The Effect of the Team Members Teaching Design vs. Regular Lectures method on the Self-efficacy of the Multiple sclerosis Patients in Iran. Randomised Controlled Trial. [PDF]

Invest Educ Enferm
Dehghani A, Fakhravari F, Hojat M.
europepmc   +1 more source

A propósito de un caso de atrofia tipo Aran-Duchenne debido a esclerosis en placas [PDF]

, 2015
P. Maza Subirats
core   +2 more sources

[XVII Post-ECTRIMS Meeting: Review of the New Developments Presented at the 2024 ECTRIMS Congress (II)]. [PDF]

Rev Neurol
Fernández Ó, Arés A, Agüera E, Aladro Y, Alonso A, Arroyo R, Brieva L, Calles C, Caminero AB, Castillo-Triviño T, Costa-Frossard L, Eichau S, Hernández MÁ, Landete L, Llaneza M, Llufriu S, Meca-Lallana JE, Meca-Lallana V, Moral E, Oreja-Guevara C, Prieto JM, Romero-Pinel L, Vilaseca A, Rodríguez-Antigüedad A.   +23 more
europepmc   +1 more source

Ocrelizumab: El primer medicamento aprobado para el tratamiento de las formas remitenterecurrente y primaria progresiva de esclerosis múltiple [PDF]

, 2017
Abril Comesaña, Sheila
core   +1 more source

[XVII Post-ECTRIMS Meeting: Review of the New Developments Presented at the 2024 ECTRIMS Congress (I)]. [PDF]

Rev Neurol
Fernández Ó, Arés A, Agüera E, Aladro Y, Alonso A, Arroyo R, Brieva L, Calles C, Caminero AB, Castillo-Triviño T, Costa-Frossard L, Eichau S, Hernández MÁ, Landete L, Llaneza M, Llufriu S, Meca-Lallana JE, Meca-Lallana V, Moral E, Oreja-Guevara C, Prieto JM, Romero-Pinel L, Vilaseca A, Rodríguez-Antigüedad A.   +23 more
europepmc   +1 more source

Access, satisfaction, adherence and safety to subcutaneous natalizumab compared to intravenous natalizumab in multiple sclerosis in a real-life cohort: first report from Latin America. [PDF]

Ther Adv Neurol Disord
Silva BA, Santajuliana F, Casas M, Lázaro L, Pita C, Cohen L, Rinaldi G, Alonso R, Míguez J, D'Alessandro S.   +9 more
europepmc   +1 more source